Eslicarbazepine acetate vs Oxcarbazepine (Trileptal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
Study BIA-2093-301 was a randomized, double-blind, placebo-controlled Phase 3 trial in 402 adults with refractory partial-onset seizures, testing once-daily eslicarbazepine acetate 400, 800 and 1200 mg against placebo. The single primary endpoint was seizure frequency over the maintenance period. The 800 mg and 1200 mg doses met it (p=0.0028 and p=0.0003); the 400 mg dose did not. Because one tested dose missed, the call is mixed, as in the wave 121 Stempeucel dose-arm precedent. Source: the peer-reviewed paper (Elger et al., Epilepsia 2009).
Reported efficacy
Time to treatment failure (up to 2 years): Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
Result source: NCT02484001
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.
Reported efficacy
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)
Result source: NCT00050934
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Eslicarbazepine acetate | Oxcarbazepine (Trileptal) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT02484001 | —Not posted · NCT00050934 |
| 50% responder rate | 30.6% vs 31%−0.4 vs placeboNCT009881562 other results
| —Not posted · NCT00050934 |
| Seizure freedom | —Not posted · NCT02484001 | —Not posted · NCT00050934 |
Seizure frequency, % change
- Eslicarbazepine acetate
- —Not posted · NCT02484001
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
50% responder rate
- Eslicarbazepine acetate
- 30.6% vs 31%−0.4 vs placeboNCT00988156
2 other results
- 54% vs 28% NCT02170077
- 41% vs 28% NCT02170077
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
Seizure freedom
- Eslicarbazepine acetate
- —Not posted · NCT02484001
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Eslicarbazepine acetate: 4 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Eslicarbazepine acetate | Oxcarbazepine (Trileptal) |
|---|---|---|
| Dropout rate | 13.3%800 mg once dailya NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 show 50 more results30.4%1200 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 10%400 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 —800 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 20.8%800 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —1200 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 30.6%1200 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —400 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 13.5%400 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —ESL PART II NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 12.9% NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT02912364 · Phase 4 · registry result, not featured evidence 25.2% NCT00910247 · Phase 3 · registry result, not featured evidence 30.6%800 mg NCT01422720 · Phase 3 · registry result, not featured evidence 40.6%1600 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence 55.4%1200 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence —1600 mg NCT01091662 · Phase 3 · registry result, not featured evidence 29.3%1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence —1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence —800 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence —1200 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence —800 mg NCT00957372 · Phase 3 · registry result, not featured evidence —1200 mg NCT00957372 · Phase 3 · registry result, not featured evidence 9.6%Esl (BIA 2-093) NCT01527513 · Phase 2 · registry result, not featured evidence —Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence —Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence 0% NCT02021461 · Phase 2 · registry result, not featured evidence —once daily NCT02170077 · Phase 2 · registry result, not featured evidence —twice daily NCT02170077 · Phase 2 · registry result, not featured evidence —Eslicarbazepine Acetate NCT00987558 · Phase 1 · registry result, not featured evidence —Eslicarbazepine Acetate + Simvasta NCT00987558 · Phase 1 · registry result, not featured evidence · combination 0% NCT00900237 · Phase 1 · registry result, not featured evidence 5% NCT00898560 · Phase 1 · registry result, not featured evidence · combination —800 mg NCT02284828 · Phase 1 · registry result, not featured evidence —1200 mg NCT02284828 · Phase 1 · registry result, not featured evidence —900 mg NCT02284828 · Phase 1 · registry result, not featured evidence —800 mg (2 x 400 mg) NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg fasting NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg fed NCT02288312 · Phase 1 · registry result, not featured evidence 0%800 mg NCT02283840 · Phase 1 · registry result, not featured evidence 0%400 mg NCT02283840 · Phase 1 · registry result, not featured evidence 5%600 mg NCT02283840 · Phase 1 · registry result, not featured evidence —Test 1 NCT02283840 · Phase 1 · registry result, not featured evidence —Test 2 NCT02283840 · Phase 1 · registry result, not featured evidence —Test 3 NCT02283840 · Phase 1 · registry result, not featured evidence n/a: no completion milestone3600 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence n/a: no completion milestone3000 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence 18.8%Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 12.5%Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 0% NCT02281591 · Phase 1 · registry result, not featured evidence —1200 mg once-daily NCT02281448 · Phase 1 · registry result, not featured evidence · combination | 14.6%b NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —800 mg once dailya NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 show 50 more results—1200 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 —400 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 —800 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —800 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —1200 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —1200 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —400 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —400 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —ESL PART II NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT02912364 · Phase 4 · registry result, not featured evidence 5.5% NCT00910247 · Phase 3 · registry result, not featured evidence 22.2%800 mg NCT01422720 · Phase 3 · registry result, not featured evidence 14.8%1600 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence 7.7%1200 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence —1600 mg NCT01091662 · Phase 3 · registry result, not featured evidence 1.7%1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence —1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence —800 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence —1200 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence —800 mg NCT00957372 · Phase 3 · registry result, not featured evidence —1200 mg NCT00957372 · Phase 3 · registry result, not featured evidence —Esl (BIA 2-093) NCT01527513 · Phase 2 · registry result, not featured evidence —Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence —Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence — NCT02021461 · Phase 2 · registry result, not featured evidence —once daily NCT02170077 · Phase 2 · registry result, not featured evidence —twice daily NCT02170077 · Phase 2 · registry result, not featured evidence —Eslicarbazepine Acetate NCT00987558 · Phase 1 · registry result, not featured evidence —Eslicarbazepine Acetate + Simvasta NCT00987558 · Phase 1 · registry result, not featured evidence · combination — NCT00900237 · Phase 1 · registry result, not featured evidence — NCT00898560 · Phase 1 · registry result, not featured evidence · combination —800 mg NCT02284828 · Phase 1 · registry result, not featured evidence —1200 mg NCT02284828 · Phase 1 · registry result, not featured evidence —900 mg NCT02284828 · Phase 1 · registry result, not featured evidence —800 mg (2 x 400 mg) NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg fasting NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg fed NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg NCT02283840 · Phase 1 · registry result, not featured evidence —400 mg NCT02283840 · Phase 1 · registry result, not featured evidence —600 mg NCT02283840 · Phase 1 · registry result, not featured evidence —Test 1 NCT02283840 · Phase 1 · registry result, not featured evidence —Test 2 NCT02283840 · Phase 1 · registry result, not featured evidence —Test 3 NCT02283840 · Phase 1 · registry result, not featured evidence —3600 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence —3000 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence —Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination —Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination — NCT02281591 · Phase 1 · registry result, not featured evidence —1200 mg once-daily NCT02281448 · Phase 1 · registry result, not featured evidence · combination | 12.5%b NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy — NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.1%800 mg once dailya NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 show 50 more results2.9%1200 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 9%400 mg once daily NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 5.9%800 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —800 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 2%1200 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —1200 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 4.2%400 mg NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 —400 mg once daily NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 8.6%ESL PART II NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3 0% NCT02912364 · Phase 4 · registry result, not featured evidence 11.7% NCT00910247 · Phase 3 · registry result, not featured evidence 15.3%800 mg NCT01422720 · Phase 3 · registry result, not featured evidence 6.3%1600 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence 6.2%1200 mg QD NCT00866775 · Phase 3 · registry result, not featured evidence 7%1600 mg NCT01091662 · Phase 3 · registry result, not featured evidence —1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence 1.7%1200 mg NCT01091662 · Phase 3 · registry result, not featured evidence 6.5%800 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence 1.4%1200 mg QD NCT00988429 · Phase 3 · registry result, not featured evidence 0%800 mg NCT00957372 · Phase 3 · registry result, not featured evidence 1.3%1200 mg NCT00957372 · Phase 3 · registry result, not featured evidence —Esl (BIA 2-093) NCT01527513 · Phase 2 · registry result, not featured evidence 3.6%Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence 7.1%Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence 2.6% NCT02021461 · Phase 2 · registry result, not featured evidence 4%once daily NCT02170077 · Phase 2 · registry result, not featured evidence 0%twice daily NCT02170077 · Phase 2 · registry result, not featured evidence 0%Eslicarbazepine Acetate NCT00987558 · Phase 1 · registry result, not featured evidence 0%Eslicarbazepine Acetate + Simvasta NCT00987558 · Phase 1 · registry result, not featured evidence · combination 0% NCT00900237 · Phase 1 · registry result, not featured evidence 0% NCT00898560 · Phase 1 · registry result, not featured evidence · combination 0%800 mg NCT02284828 · Phase 1 · registry result, not featured evidence 0%1200 mg NCT02284828 · Phase 1 · registry result, not featured evidence 0%900 mg NCT02284828 · Phase 1 · registry result, not featured evidence 0%800 mg (2 x 400 mg) NCT02288312 · Phase 1 · registry result, not featured evidence 0%800 mg fasting NCT02288312 · Phase 1 · registry result, not featured evidence 0%800 mg fed NCT02288312 · Phase 1 · registry result, not featured evidence —800 mg NCT02283840 · Phase 1 · registry result, not featured evidence —400 mg NCT02283840 · Phase 1 · registry result, not featured evidence —600 mg NCT02283840 · Phase 1 · registry result, not featured evidence 0%Test 1 NCT02283840 · Phase 1 · registry result, not featured evidence 0%Test 2 NCT02283840 · Phase 1 · registry result, not featured evidence 0%Test 3 NCT02283840 · Phase 1 · registry result, not featured evidence 0%3600 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence 0%3000 mg Once Daily NCT01879332 · Phase 1 · registry result, not featured evidence 0%Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 0%Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 0% NCT02281591 · Phase 1 · registry result, not featured evidence 5%1200 mg once-daily NCT02281448 · Phase 1 · registry result, not featured evidence · combination | 2.1%b NCT00975715 · Phase 2/3 · combination show 5 more results0%Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination 0%Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence 0%450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence 0% NCT01678976 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 800 mg once dailya dizziness 14.3% (placebo 2%) headache 9.2% (placebo 5.9%) somnolence 9.2% (placebo 2%) NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 show 40 more results1200 mg once daily dizziness 13.7% (placebo 2%) diplopia 10.8% (placebo 0%) headache 10.8% (placebo 5.9%) NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 400 mg once daily somnolence 6% (placebo 2%) headache 5% (placebo 5.9%) dizziness 4% (placebo 2%) NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3 800 mg dizziness 29.7% (placebo 10%) somnolence 16.8% (placebo 17%) diplopia 14.9% (placebo 4%) NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 1200 mg dizziness 43.9% (placebo 10%) somnolence 21.4% (placebo 17%) headache 19.4% (placebo 9%) NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 400 mg dizziness 22.9% (placebo 10%) somnolence 15.6% (placebo 17%) headache 12.5% (placebo 9%) NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 dizziness 26.5% (placebo 10%) headache 15.7% (placebo 9%) somnolence 12% (placebo 17%) NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3 fatigue 34.5% headache 10.3% clouded vision 3.4% NCT02912364 · Phase 4 · registry result, not featured evidence headache 23.4% dizziness 16.8% nasopharyngitis 8.8% NCT00910247 · Phase 3 · registry result, not featured evidence 800 mg dizziness 12.5% somnolence 9.7% convulsion 8.3% NCT01422720 · Phase 3 · registry result, not featured evidence 1600 mg QD dizziness 24.2% headache 20.3% somnolence 18% NCT00866775 · Phase 3 · registry result, not featured evidence 1200 mg QD dizziness 27.7% headache 21.5% fatigue 20% NCT00866775 · Phase 3 · registry result, not featured evidence 1600 mg headache 28.1% dizziness 21.1% solmnolence 8.8% NCT01091662 · Phase 3 · registry result, not featured evidence 1200 mg headache 19% dizziness 10.3% nausea 10.3% NCT01091662 · Phase 3 · registry result, not featured evidence 800 mg QD dizziness 15.7% (placebo 8.5%) headache 9.3% (placebo 7.6%) nausea 7.4% (placebo 4.9%) NCT00988429 · Phase 3 · registry result, not featured evidence 1200 mg QD dizziness 26.2% (placebo 8.5%) somnolence 17.1% (placebo 5.4%) nausea 15.2% (placebo 4.9%) NCT00988429 · Phase 3 · registry result, not featured evidence 800 mg dizziness 18.8% (placebo 10.3%) somnolence 12.9% (placebo 9.2%) headache 5.9% (placebo 11.5%) NCT00957372 · Phase 3 · registry result, not featured evidence 1200 mg dizziness 30% (placebo 10.3%) somnolence 13.8% (placebo 9.2%) headache 10% (placebo 11.5%) NCT00957372 · Phase 3 · registry result, not featured evidence headache 9.6% (placebo 15%) somnolence 6% (placebo 5%) vomiting 6% (placebo 2.5%) NCT01527513 · Phase 2 · registry result, not featured evidence headache 5.4% (placebo 15%) respiratory tract infection viral 5.4% (placebo 0%) convulsion 3.6% (placebo 0%) NCT01527513 · Phase 2 · registry result, not featured evidence once daily somnolence 6% (placebo 0%) hair loss 4% (placebo 2.1%) headache 4% (placebo 6.4%) NCT02170077 · Phase 2 · registry result, not featured evidence twice daily headache 17.4% (placebo 6.4%) dizziness 10.9% (placebo 2.1%) vomiting 10.9% (placebo 2.1%) NCT02170077 · Phase 2 · registry result, not featured evidence fatigue 40% headache 20% rash morbilliform 10% NCT00987558 · Phase 1 · registry result, not featured evidence orthostatic hypotension 10% headache 6.7% pharyngitis 3.3% NCT00987558 · Phase 1 · registry result, not featured evidence · combination dizziness 42.9% fatigue 28.6% headache 28.6% NCT00900237 · Phase 1 · registry result, not featured evidence somnolence 40% headache 30% dizziness 25% NCT00898560 · Phase 1 · registry result, not featured evidence · combination 800 mg nausea 11.5% (placebo 19.2%) dizziness 7.7% (placebo 3.8%) headache 7.7% (placebo 3.8%) NCT02284828 · Phase 1 · registry result, not featured evidence 1200 mg headache 7.7% (placebo 3.8%) hypoaesthesia 7.7% (placebo 0%) paraesthesia 7.7% (placebo 3.8%) NCT02284828 · Phase 1 · registry result, not featured evidence 900 mg nausea 7.7% (placebo 19.2%) somnolence 7.7% (placebo 11.5%) abdominal distension 3.8% (placebo 3.8%) NCT02284828 · Phase 1 · registry result, not featured evidence 800 mg (2 x 400 mg) cpk increased 5.9% somnolence 5.9% diarrhoea 0% NCT02288312 · Phase 1 · registry result, not featured evidence 800 mg fasting diarrhoea 5.6% tonsillitis 5.6% tooth extraction 5.6% NCT02288312 · Phase 1 · registry result, not featured evidence 800 mg fed cpk increased 5.9% pregnancy 5.9% somnolence 5.9% NCT02288312 · Phase 1 · registry result, not featured evidence somnolence 20% back pain 5% eye pruritus 5% NCT02283840 · Phase 1 · registry result, not featured evidence somnolence 31.6% dizziness 5.3% electrocardigram qt corrected interval prolonged 5.3% NCT02283840 · Phase 1 · registry result, not featured evidence somnolence 20% constipation 5% disturbance in attention 5% NCT02283840 · Phase 1 · registry result, not featured evidence 3600 mg Once Daily dizziness 83.3% (placebo 25%) somnolence 66.7% (placebo 25%) vomiting 50% (placebo 0%) NCT01879332 · Phase 1 · registry result, not featured evidence 3000 mg Once Daily dizziness 83.3% (placebo 25%) fatigue 66.7% (placebo 0%) vomiting 66.7% (placebo 0%) NCT01879332 · Phase 1 · registry result, not featured evidence somnolence 87.5% paraesthesia oral 50% headache 43.8% NCT02283814 · Phase 1 · registry result, not featured evidence · combination somnolence 81.3% abdominal distension 43.8% fatigue 37.5% NCT02283814 · Phase 1 · registry result, not featured evidence · combination headache 37.5% dizziness 25% accidental injury 12.5% NCT02281591 · Phase 1 · registry result, not featured evidence 1200 mg once-daily somnolence 73.7% dizziness 52.6% constipation 26.3% NCT02281448 · Phase 1 · registry result, not featured evidence · combination | b somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · combination show 5 more resultssomnolence 75% dizziness 56.3% headache 50% NCT03695094 · Phase 1 · registry result, not featured evidence · combination somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy headache 100% dizziness 85.7% back pain 71.4% NCT00900237 · Phase 1 · registry result, not featured evidence 450 mg Bid dizziness 54.5% somnolence 54.5% frontal headache 18.2% NCT01679002 · Phase 1 · registry result, not featured evidence dizziness 23.1% headache 23.1% nodule subcutaneous 15.4% NCT01678976 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 40 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Eslicarbazepine acetate
show 2 more results
show 2 more results
show 2 more results
show 8 more results
show 1 more result
show 3 more results
+ 30 further endpoints in the CSV export.
Focal Onset Seizures
Shared mechanism: Voltage-gated sodium channel · full Focal Onset Seizures pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
Study BIA-2093-301 was a randomized, double-blind, placebo-controlled Phase 3 trial in 402 adults with refractory partial-onset seizures, testing once-daily eslicarbazepine acetate 400, 800 and 1200 mg against placebo. The single primary endpoint was seizure frequency over the maintenance period. The 800 mg and 1200 mg doses met it (p=0.0028 and p=0.0003); the 400 mg dose did not. Because one tested dose missed, the call is mixed, as in the wave 121 Stempeucel dose-arm precedent. Source: the peer-reviewed paper (Elger et al., Epilepsia 2009).
Reported efficacy
PART I - Seizure Frequency (12-week maintenance period); PART II - Nº of Treatment-Emergent Adverse Events (TEAE) (1 year): Seizure frequency per 4 weeks over the double-blind treatment period vs placebo: ESL 800 mg and 1200 mg p<0.001, ESL 400 mg not significant; responder rate 13.0% placebo, 16.7% 400 mg, 40.0% 800 mg, 37.1% 1200 mg (Ben-Menachem et al., Epilepsy Res 2010, study BIA-2093-302). (mixed)
Result source: NCT00957047
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00975715 · Phase 2/3 · completed
The study randomized 48 participants to TRI476 and 51 to placebo and was double-blind. Its primary clinical endpoint was change in seizure frequency, but statistical significance was not reported, so the trial provides useful controlled evidence without clearly establishing that the primary endpoint was met.
No aligned efficacy figure on record for this race.
Results for Focal Onset Seizures
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Eslicarbazepine acetate: 3 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Eslicarbazepine acetate | Oxcarbazepine (Trileptal) |
|---|---|---|
| Dropout rate | 9.6%Esl (BIA 2-093)a NCT01527513 · Phase 2 · registry result, not featured evidence show 2 more results—Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence —Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence | 14.6%a NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Esl (BIA 2-093)a NCT01527513 · Phase 2 · registry result, not featured evidence show 2 more results—Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence —Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence | 12.5%a NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
| Serious AEs | —Esl (BIA 2-093)a NCT01527513 · Phase 2 · registry result, not featured evidence show 2 more results3.6%Part I - ESL NCT01527513 · Phase 2 · registry result, not featured evidence 7.1%Part II - ESL NCT01527513 · Phase 2 · registry result, not featured evidence | 2.1%a NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a headache 9.6% (placebo 15%) somnolence 6% (placebo 5%) vomiting 6% (placebo 2.5%) NCT01527513 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 5.4% (placebo 15%) respiratory tract infection viral 5.4% (placebo 0%) convulsion 3.6% (placebo 0%) NCT01527513 · Phase 2 · registry result, not featured evidence | a somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Eslicarbazepine acetate
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Oxcarbazepine (Trileptal)'s landscape